210 related articles for article (PubMed ID: 20179708)
1. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
Sutherland S; Ashley S; Miles D; Chan S; Wardley A; Davidson N; Bhatti R; Shehata M; Nouras H; Camburn T; Johnston SR
Br J Cancer; 2010 Mar; 102(6):995-1002. PubMed ID: 20179708
[TBL] [Abstract][Full Text] [Related]
2. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
Bachelot T; Romieu G; Campone M; Diéras V; Cropet C; Dalenc F; Jimenez M; Le Rhun E; Pierga JY; Gonçalves A; Leheurteur M; Domont J; Gutierrez M; Curé H; Ferrero JM; Labbe-Devilliers C
Lancet Oncol; 2013 Jan; 14(1):64-71. PubMed ID: 23122784
[TBL] [Abstract][Full Text] [Related]
3. An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.
Capri G; Chang J; Chen SC; Conte P; Cwiertka K; Jerusalem G; Jiang Z; Johnston S; Kaufman B; Link J; Ro J; Schütte J; Oliva C; Parikh R; Preston A; Rosenlund J; Selzer M; Zembryki D; De Placido S
Ann Oncol; 2010 Mar; 21(3):474-480. PubMed ID: 19815649
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
Cetin B; Benekli M; Turker I; Koral L; Ulas A; Dane F; Oksuzoglu B; Kaplan MA; Koca D; Boruban C; Yilmaz B; Sevinc A; Berk V; Uncu D; Harputluoglu H; Coskun U; Buyukberber S
J Chemother; 2014 Oct; 26(5):300-5. PubMed ID: 24112786
[TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
Lin NU; Eierman W; Greil R; Campone M; Kaufman B; Steplewski K; Lane SR; Zembryki D; Rubin SD; Winer EP
J Neurooncol; 2011 Dec; 105(3):613-20. PubMed ID: 21706359
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.
Ro J; Park S; Kim S; Kim TY; Im YH; Rha SY; Chung JS; Moon H; Santillana S
BMC Cancer; 2012 Jul; 12():322. PubMed ID: 22839200
[TBL] [Abstract][Full Text] [Related]
7. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE
Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694
[TBL] [Abstract][Full Text] [Related]
8. Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer.
Han SW; Cha Y; Paquet A; Huang W; Weidler J; Lie Y; Sherwood T; Bates M; Haddad M; Park IH; Oh DY; Lee KS; Im SA; Bang YJ; Ro J; Kim TY
PLoS One; 2012; 7(7):e39943. PubMed ID: 22848366
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience.
Crivellari D; Spazzapan S; Lombardi D; Militello L; Torrisi E; Russo AE; Sorio R; Talamini R; Miolo G; Carli P; Veronesi A
Tumori; 2012; 98(1):33-8. PubMed ID: 22495699
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer].
Chiba A; Shimizu S; Yoshida A; Inaba M; Matsuura H; Ino H; Suganuma N; Inari H; Yamanaka T; Kuroda K; Mukaibashi T; Matsuo A; Kojima I
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1675-9. PubMed ID: 23152018
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
Metro G; Foglietta J; Russillo M; Stocchi L; Vidiri A; Giannarelli D; Crinò L; Papaldo P; Mottolese M; Cognetti F; Fabi A; Gori S
Ann Oncol; 2011 Mar; 22(3):625-630. PubMed ID: 20724575
[TBL] [Abstract][Full Text] [Related]
13. Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients.
Xu BH; Jiang ZF; Chua D; Shao ZM; Luo RC; Wang XJ; Liu DG; Yeo W; Yu SY; Newstat B; Preston A; Martin AM; Chi HD; Wang L
Chin J Cancer; 2011 May; 30(5):327-35. PubMed ID: 21527065
[TBL] [Abstract][Full Text] [Related]
14. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Pivot X; Manikhas A; Żurawski B; Chmielowska E; Karaszewska B; Allerton R; Chan S; Fabi A; Bidoli P; Gori S; Ciruelos E; Dank M; Hornyak L; Margolin S; Nusch A; Parikh R; Nagi F; DeSilvio M; Santillana S; Swaby RF; Semiglazov V
J Clin Oncol; 2015 May; 33(14):1564-73. PubMed ID: 25605838
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
Uncu D; Bayoglu IV; Arslan UY; Kucukoner M; Artac M; Koca D; Oguz A; Demirci U; Arpaci E; Dogan M; Kucukzeybek Y; Turker I; Isikdogan A; Guler T; Zengin N
Asian Pac J Cancer Prev; 2015; 16(9):4127-31. PubMed ID: 25987098
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.
Pierga JY; Bidard FC; Cropet C; Tresca P; Dalenc F; Romieu G; Campone M; Mahier Aït-Oukhatar C; Le Rhun E; Gonçalves A; Leheurteur M; Dômont J; Gutierrez M; Curé H; Ferrero JM; Labbe-Devilliers C; Bachelot T
Ann Oncol; 2013 Dec; 24(12):2999-3004. PubMed ID: 24013510
[TBL] [Abstract][Full Text] [Related]
17. A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer.
Janni W; Sarosiek T; Karaszewska B; Pikiel J; Staroslawska E; Potemski P; Salat C; Brain E; Caglevic C; Briggs K; Desilvio M; Marini L; Papadimitriou C
Breast Cancer Res Treat; 2014 Feb; 143(3):493-505. PubMed ID: 24402830
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab emtansine for HER2-positive advanced breast cancer.
Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K;
N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib for the treatment of HER2-overexpressing breast cancer.
Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
